ATHM [Autohome] 6-K: Autohome Inc. Appoints New Independent Director to the

[Autohome Inc. Appoints New Independent Director to the Board BEIJING, December 9, 2014 — Autohome Inc. (NYSE: ATHM) (“Autohome” or the “Company”), the leading online destination for automobile consumers in China, today announced the appointment of Mr. Guangfu Cui as an independent director and a member of the audit committee and the compensation committee of the board of directors of] [FORM 6-K Autohome Inc. 10th Floor Tower B, CEC Plaza 3 Dan Ling Street Haidian District, Beijing 100080 The People’s Republic of China x ¨ Form 20-F ¨ ¨ Autohome Inc. James Zhi Qin Director and Chief Executive Officer 3 6-K 1 d834446d6k.htm FORM 6-K]

HSOL [Hanwha Q CELLS] 6-K: (Original Filing)

[CREATING A NEW GLOBAL LEADER IN SOLAR POWER M&A Announcement December 8, 2014 Disclaimer Additional Information about the Transaction The total revenue for SolarOne and Q CELLS for the six month period ended June 30, 2014 set out below does not constitute pro forma financial information and is not necessarily indicative of or intended to represent the results that would] [Hanwha SolarOne / Q CELLS Announcement FREQUENTLY ASKED QUESTIONS For the Financial Community 1. What’s the rationale for the combination? The combination creates a new leader in solar power with a solar cell production capacity of 3.28 gigawatts. We believe combined global scale will allow us to increase our competitiveness, increase efficiency, reduce manufacturing costs and improve our growth profile] [HANWHA SOLARONE CO., LTD 6-K 1 d834576d6k.htm FORM 6-K]

By | 2016-04-03T01:33:09+00:00 December 9th, 2014|Categories: Chinese Stocks, HSOL, SEC Original|Tags: , , , , , |0 Comments

HSOL [Hanwha Q CELLS] 6-K: CREATING A NEW GLOBAL LEADER IN SOLAR POWER

[CREATING A NEW GLOBAL LEADER IN SOLAR POWER M&A Announcement December 8, 2014 Disclaimer Additional Information about the Transaction The total revenue for SolarOne and Q CELLS for the six month period ended June 30, 2014 set out below does not constitute pro forma financial information and is not necessarily indicative of or intended to represent the results that would] [Hanwha SolarOne / Q CELLS Announcement FREQUENTLY ASKED QUESTIONS For the Financial Community 1. What’s the rationale for the combination? The combination creates a new leader in solar power with a solar cell production capacity of 3.28 gigawatts. We believe combined global scale will allow us to increase our competitiveness, increase efficiency, reduce manufacturing costs and improve our growth profile] [HANWHA SOLARONE CO., LTD 6-K 1 d834576d6k.htm FORM 6-K]

By | 2016-04-03T01:34:52+00:00 December 9th, 2014|Categories: Chinese Stocks, HSOL, Webplus ver|Tags: , , , , , |0 Comments

GAME [Shanda Games] SC 13D/A: (Original Filing)

[CUSIP No. 81941U105 (1) Names of reporting persons Zhongrong Shengda Investment Holdings (Hong Kong) Company Limited (2) Check the appropriate box if a member of a group (see instructions) ¨ x (a) (3) SEC use only (4) Source of funds (see instructions) BK (5) ¨ (6) Citizenship or place of organization Hong Kong]

By | 2016-04-03T08:55:00+00:00 December 9th, 2014|Categories: Chinese Stocks, GAME, SEC Original|Tags: , , , , , |0 Comments

GAME [Shanda Games] SC 13D/A: CUSIP No. 81941U105 (1) Names of reporting persons

[CUSIP No. 81941U105 (1) Names of reporting persons Zhongrong Shengda Investment Holdings (Hong Kong) Company Limited (2) Check the appropriate box if a member of a group (see instructions) ¨ x (a) (3) SEC use only (4) Source of funds (see instructions) BK (5) ¨ (6) Citizenship or place of organization Hong Kong]

By | 2016-04-03T08:56:16+00:00 December 9th, 2014|Categories: Chinese Stocks, GAME, Webplus ver|Tags: , , , , , |0 Comments

VNET [21Vianet] CORRESP: (Original Filing)

[21Vianet Group, Inc. M5, 1 Jiuxianqiao East Road Chaoyang District Beijing, 100016 The People’s Republic of China December 9, 2014 VIA EDGAR Craig Wilson, Senior Assistant Chief Accountant Melissa Walsh, Staff Accountant Jeffrey Kauten, Staff Attorney Matthew Crispino, Staff Attorney Division of Corporation Finance 100 F Street, N.E. Re: 21Vianet Group, Inc. (the “Company”) Form 20-F for the Fiscal Year]

VNET [21Vianet] CORRESP: 21Vianet Group, Inc. M5, 1 Jiuxianqiao East Road

[21Vianet Group, Inc. M5, 1 Jiuxianqiao East Road Chaoyang District Beijing, 100016 The People’s Republic of China December 9, 2014 VIA EDGAR Craig Wilson, Senior Assistant Chief Accountant Melissa Walsh, Staff Accountant Jeffrey Kauten, Staff Attorney Matthew Crispino, Staff Attorney Division of Corporation Finance 100 F Street, N.E. Re: 21Vianet Group, Inc. (the “Company”) Form 20-F for the Fiscal Year]

TPI [TIANYIN PHARMACEUTICAL] 10-K: (Original Filing)

[TIANYIN PHARMACEUTICAL CO., INC FORM 10-K INDEX Page PART I Item 1 Description of Business 3 Item 1A Risk Factors 14 Item 1B Unresolved Staff Comments 25 Item 2 Description of Property 26 Item 3 Legal Proceedings 26 Item 4 Removed and Reserved 26 PART II Item 5 Market for Common Equity and Related Stockholder Matters and Issuer Purchases of] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James J. Tong, certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer EX-32.1 4 f10k2014ex32i_tianyinpharma.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James J. Tong Chief Financial Officer EX-32.2 5 f10k2014ex32ii_tianyinpharma.htm CERTIFICATION]

By | 2016-03-19T15:06:43+00:00 December 9th, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments

TPI [TIANYIN PHARMACEUTICAL] 10-K: TIANYIN PHARMACEUTICAL CO., INC FORM 10-K INDEX Page

[TIANYIN PHARMACEUTICAL CO., INC FORM 10-K INDEX Page PART I Item 1 Description of Business 3 Item 1A Risk Factors 14 Item 1B Unresolved Staff Comments 25 Item 2 Description of Property 26 Item 3 Legal Proceedings 26 Item 4 Removed and Reserved 26 PART II Item 5 Market for Common Equity and Related Stockholder Matters and Issuer Purchases of] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James J. Tong, certify that: 1. I have reviewed this annual report on Form 10-K of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer, Chief Accounting Officer EX-32.1 4 f10k2014ex32i_tianyinpharma.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James J. Tong Chief Financial Officer EX-32.2 5 f10k2014ex32ii_tianyinpharma.htm CERTIFICATION]

By | 2016-03-19T15:07:46+00:00 December 9th, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments

ACTS [Actions Semiconductor] 6-K: (Original Filing)

[Dear Shareholders, Our Chairman is in receipt of a letter from a shareholder holding approximately 5.4 million shares or 9.2% of our total ADSs. This shareholder chooses to publish his letters to our Chairman, as he has a right to do. We continue to welcome dialog with our shareholders in any forum. In order that all shareholders may see our] []

By | 2016-03-19T17:06:37+00:00 December 9th, 2014|Categories: ACTS, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar